Robert Lee Page ii, PharmD, MSPH, FAHA, FCCP, FASCcP, FASHP, BCPS, Vahram Ghushchyan, PhD, Kavita Nair, PhD, James T. Kenney, RPh, MBA
Despite advances in life-saving medical interventions and pharmacotherapies, cardiovascular disease (CVD) continues to be a leading killer in the United States.1 The spectrum of CVD consists of hypertension, chronic heart disease (CHD; including myocardial infarction [MI] and angina), heart failure, and stroke.
Prevention Efforts before Disease Strikes the Key to a Healthy Population of Young Adults
Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications
Karmella T. Thomas, BS, RD, Katie B. Lyons, MS II, Loida D. Nguyen, PharmD, BCPS, Raymond A. Plodkowski, MD, Quang T. Nguyen, DO, FACP, FACE, FTOS
Diabetes is the leading cause of kidney failure, nontraumatic lower-limb amputations, and new cases of blindness among adults in the United States.
New Therapies with Novel Mechanisms of Action Are Urgently Needed for Type 2 Diabetes
The prevalence of diabetes has increased dramatically in recent decades. This trend highlights the importance of prevention and appropriate therapy to reduce cardiovascular events in patients with diabetes. Reaching adequate blood glucose control is important in decreasing microvascular complications associated with diabetes; however, good lipid management is vital for reducing the incidence of cardiovascular events in patients with diabetes.1-4
The Time Is Now to Promote Aggressive Lipid Management to Prevent Macrovascular Complications in Patients with Type 2 Diabetes
The Janus kinase (JAK) 1/2 inhibitor ruxolitinib dramatically improves response rates in treating 3 forms of myelofibrosis, according to results from 2 randomized phase 3 clinical trials, known as COMFORT (Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment) I and II.
In both COMFORT trials, ruxolitinib was significantly superior to the best available therapy in reducing spleen size and symptom burden and improving quality of life. The studies are the first randomized trials of drug therapy for myelofibrosis.
A new regimen of oral busulfan (Myleran) and melphalan (Alkeran) extended event-free survival over a regimen of carboplatin (Paraplatin), etoposide (Eposin), and melphalan (CEM) in a phase 3 clinical trial of patients with high-risk pediatric neuroblastoma.
The trial was terminated early once the superiority of the busulfan-melphalan myeloablative regimen became evident, said lead investigator Ruth Ladenstein, MD, Associate Professor of Pediatrics, University of Vienna, and St Anna Children’s Cancer Research Institute, Vienna.
Anticoagulation Bridging Therapy Patterns in Patients Undergoing Total Hip or Total Knee Replacement in a US Health Plan: Real-World Observations and Implications
An estimated 350,000 to 600,000 American patients experience venous thromboembolism (VTE) annually, which includes deep-vein thrombosis and pulmonary embolism.1-5 Patients undergoing total hip replacement (THR) or total knee replacement (TKR) surgery are at high risk for VTE, because the large veins in the legs carrying blood back to the heart are significantly injured during these procedures.6,7 As a result of the aging and increasingly obese US population, an estimated 500,000 THR operations and 3.5 million TKR operations are expected to be performed by 2030.8
Anticoagulation Bridging Therapy after Total Hip or Knee Replacement: A Missed Opportunity?
Modeling Costs and Outcomes Associated with a Treatment Algorithm for Problem Bleeding Episodes in Patients with Severe Hemophilia A and High-Titer Inhibitors
Patrick Bonnet, PharmD, Alessandro Gringeri, MD, Edward Gomperts, MD, Cindy Anne Leissinger, MD, Roseline d’Oiron, MD, Jerome Teitel, MD, Guy Young, MD, Meg Franklin, PharmD, PhD, Bruce Ewenstein, MD, Erik Berntorp, MD, PhD
Factor replacement therapy is the standard treatment for hemophilia. However, some patients with hemophilia develop inhibitors (alloantibodies) against the clotting factor administered. The development of these clotting inhibitors may render replacement therapy ineffective and, consequently, increase morbidity because of the inability to control or prevent hemorrhages. Inhibitor development has been reported to occur in as many as 33% of patients with hemophilia A, and as many as 7.5% of patients with hemophilia B.1-3
Potential Cost-Savings Using a Treatment Algorithm for Problem Bleeding Episodes in Patients with Hemophilia and Inhibitors
Andrea Henry, PharmD, MBA, Goldina Ikezuagu Erowele, PharmD, Uche Anadu Ndefo, PharmD, BCPS, Jackie Milton-Brown, PharmD, Enock Anassi, PharmD, MD, Wendy Green, PharmD, MPA, Adriana Alvidrez, PharmD, BCPS, Alphonsus U. Okpara, PharmD
The Harris County Hospital District (HCHD) is an integrated public healthcare system for Harris County, TX, the nation’s third most populous county.1 More than 27% of Harris County residents are uninsured, and Texas state law requires counties to serve the indigent; therefore, most of these uninsured patients receive care at HCHD.2 HCHD is comprised of 3 hospitals, 13 community health centers, 13 satellite homeless shelter clinics, 8 school-based clinics, 4 mobile health clinics, and a free-standing dental center.
A Collaborative Approach to Drug Selection, Driven by Clinical Outcomes Excellence
It is well known that the use of prescription opioid medications, more than other medications, is associated with risks for misuse, abuse, and diversion.1-3 The government and pharmaceutical companies have addressed this issue by implementing specific strategies to minimize the risks associated with prescription drugs in general and with opioids in particular.
Just Say No
Page 9 of 12
Results 81 - 90 of 116
Results 81 - 90 of 116